Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal esketamine plus oral antidepressant for treatment-resistant depression
2014-004584-20Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Esketamine plus oral antidepressant with Placebo plus oral antidepressant (2 arms). Primary endpoint: Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at end of double-blind induction phase. Started Jun 2015; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2014-004584-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004584-20.